Cabozantinib FDA approved for treatment of patients with advanced renal cell carcinoma

Non-Sponsored Content

By: scienterrific | Last updated: 19 December 2017 | In: US FDA Onc\Haem Approvals, Uncategorised

Article Keywords

FDA, cabozantinib, Exelixis, Cabometyx

On 19 December 2017, the FDA granted regular approval to cabozantinib (Cabometyx®, Exelixis) for treatment of patients with advanced renal cell carcinoma (RCC).

Disclaimer

This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).

Non-Sponsored Content

Cabozantinib FDA approved for treatment of patients with advanced renal cell carcinoma

Article Keywords

Disclaimer

YOU MAY ALSO LIKE

Leave a Reply